|
FY2025
12 months to Dec 31, 2025
|
FY2024
12 months to Dec 31, 2024
|
FY2023
12 months to Dec 31, 2023
|
FY2022
12 months to Dec 31, 2022
|
FY2021
12 months to Dec 31, 2021
|
|
|---|---|---|---|---|---|
| Revenue (note 3) | |||||
| Cost of revenue, including cost of revenue from related parties of $62,498, $39,313, and $31,240 for the years ended December 31, 2025, 2024, and 2023, respectively (note 13) | |||||
| Gross profit | |||||
| Operating expenses: | |||||
| Sales and marketing | |||||
| Research and development | |||||
| General and administrative | |||||
| Total operating expenses | |||||
| Loss from operations | |||||
| Interest income | |||||
| Interest expense | |||||
| Realized gain from sale of short-term investments | |||||
| Unrealized gain (loss) on short-term investments | |||||
| Other (expense) income, net | |||||
| Income from equity method investments | |||||
| Income before income taxes | |||||
| Income tax expense (note 16) | |||||
| Net income | |||||
| Foreign currency translation adjustment, net of tax | |||||
| Unrealized gain on available-for-sale investments, net of tax | |||||
| Comprehensive income | |||||
| Less: Comprehensive income attributable to non-controlling interests | |||||
| Comprehensive income attributable to ACM Research, Inc. | |||||
| Net income per common stock (note 2): | |||||
| Basic (in dollars per share) | |||||
| Diluted (in dollars per share) | |||||
| Weighted average common stock outstanding used in computing per share amounts (note 2): | |||||
| Basic (in shares) | |||||
| Diluted (in shares) | |||||
| Less: Net income attributable to non-controlling interests | |||||
| Net income attributable to ACM Research, Inc. | |||||
Loading...